{'text': "European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe", 'publisher': {'href': 'https://www.amgen.com', 'title': 'Amgen'}, 'created_at': 'Thu, 17 Dec 2015 08:00:00 GMT', 'description': "European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe  Amgen", 'url': 'https://news.google.com/rss/articles/CBMi-AFBVV95cUxOLUtlYmF6aGpHTTlfRXAweGpBQngyZFcxNDBMT2RxNHFLOVlGS3I2bHFIa3BhLVBUVlBVd3VqSS1DMHFFbGhISk55Qi1jLUN4cEhQWk5CRmp4cFF5VzN2NkFBWTRrTTFIcDVPVjRHRnVBLVJQQWVpZnJObmJHYm90V3Z5T241dVp0N0FHNjRFTW9GMWtqVGVFYThNQktaZTNHalJvMWVPYWVtQVpDcDMxREozenJ1U1NhdlprenkzVVQ3LUFwWGEydjRVUFRfMlZLbk5DVFNRS3lvMlJsNlFsc2t1ODBmVmFUcEJhU252VzRoNWRiZkh6RA?oc=5&hl=en-US&gl=US&ceid=US:en'}
